PMID- 29246028
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 59
DP  - 2017 Nov 21
TI  - Challenges and future of biomarker tests in the era of precision oncology: Can we 
      rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) 
      to select the optimal patients for matched therapy?
PG  - 100863-100898
LID - 10.18632/oncotarget.19809 [doi]
AB  - Molecular techniques have improved our understanding of the pathogenesis of 
      cancer development. These techniques have also fueled the rational development of 
      targeted drugs for patient populations stratified by their genetic 
      characteristics. These novel methods have changed the classic paradigm of 
      diagnostic pathology; among them are IHC, FISH, polymerase chain reaction (PCR) 
      and microarray technology. IHC and FISH detection methods for human epidermal 
      growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR) and 
      programmed death ligand-1 (PD-L1) were recently approved by the Food and Drug 
      Administration (FDA) as routine clinical practice for cancer patients. Here, we 
      discuss general challenges related to the predictive power of these molecular 
      biomarkers for targeted therapy in cancer medicine. We will also discuss the 
      prospects of utilizing new biomarkers for fibroblast growth factor receptor 
      (FGFR) and hepatocyte growth factor receptor (cMET/MET) targeted therapies for 
      developing new and robust predictive biomarkers in oncology.
FAU - Chae, Young Kwang
AU  - Chae YK
AD  - Developmental Therapeutics Program of the Division of Hematology Oncology, 
      Chicago, IL, USA.
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
FAU - Arya, Ayush
AU  - Arya A
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
FAU - Chiec, Lauren
AU  - Chiec L
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
FAU - Shah, Hiral
AU  - Shah H
AD  - Developmental Therapeutics Program of the Division of Hematology Oncology, 
      Chicago, IL, USA.
FAU - Rosenberg, Ari
AU  - Rosenberg A
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
FAU - Patel, Sandip
AU  - Patel S
AD  - University of California San Diego, San Diego, CA, USA.
FAU - Raparia, Kirtee
AU  - Raparia K
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
FAU - Choi, Jaehyuk
AU  - Choi J
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
FAU - Wainwright, Derek A
AU  - Wainwright DA
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
FAU - Villaflor, Victoria
AU  - Villaflor V
AD  - Developmental Therapeutics Program of the Division of Hematology Oncology, 
      Chicago, IL, USA.
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
FAU - Cristofanilli, Massimo
AU  - Cristofanilli M
AD  - Developmental Therapeutics Program of the Division of Hematology Oncology, 
      Chicago, IL, USA.
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
FAU - Giles, Francis
AU  - Giles F
AD  - Developmental Therapeutics Program of the Division of Hematology Oncology, 
      Chicago, IL, USA.
AD  - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, 
      IL, USA.
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170801
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5725070
OTO - NOTNLM
OT  - FISH
OT  - IHC
OT  - biomarker
OT  - predictive
OT  - targeted therapy
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2017/12/17 06:00
MHDA- 2017/12/17 06:01
PMCR- 2017/11/21
CRDT- 2017/12/17 06:00
PHST- 2016/10/13 00:00 [received]
PHST- 2017/04/11 00:00 [accepted]
PHST- 2017/12/17 06:00 [entrez]
PHST- 2017/12/17 06:00 [pubmed]
PHST- 2017/12/17 06:01 [medline]
PHST- 2017/11/21 00:00 [pmc-release]
AID - 19809 [pii]
AID - 10.18632/oncotarget.19809 [doi]
PST - epublish
SO  - Oncotarget. 2017 Aug 1;8(59):100863-100898. doi: 10.18632/oncotarget.19809. 
      eCollection 2017 Nov 21.